USE OF PHARMACEUTICAL COMPOSITION FOR TREATING LUNG CANCER

    公开(公告)号:EP4349340A1

    公开(公告)日:2024-04-10

    申请号:EP22815267.4

    申请日:2022-05-31

    申请人: Hung, Mien-Chie

    摘要: Disclosed is the use of a pharmaceutical composition for treating lung cancer. The pharmaceutical composition comprises a nucleoprotein kinase C-δ inhibitor, and the nucleoprotein kinase C-δ inhibitor is abemaciclib, albendazole, amoxanpine, ceritinib dihydrochloride, cobimetinib, dabigatran etexilate, dabrafenib, emamectin, ingenol, ixazomib, midostaurin, niclosamide, nintedanib ethanesulfonate salt, ponatinib, raloxifene, regorafenib, ruxolitinib, tafenoquine, travoprost, mitochondrial antioxidant, vortioxetine, or derivatives thereof. Therefore, the pharmaceutical composition can be used for preparing drugs for treating lung cancer.